Long-Term Treatment of Niemann-Pick Type Cl Disease With Intrathecal 2-Hydroxypropyl-β-Cyclodextrin

被引:53
作者
Berry-Kravis, Elizabeth [1 ,2 ,3 ]
Chin, Jamie [1 ]
Hoffmann, Anne [1 ,4 ]
Winston, Amy [4 ]
Stoner, Robin [4 ]
LaGorio, Lisa [4 ]
Friedmann, Katherine [1 ]
Hernandez, Mariana [1 ]
Ory, Daniel S. [5 ]
Porter, Forbes D. [6 ]
O'Keefe, Joan A. [2 ,7 ]
机构
[1] Rush Univ, Med Ctr, Dept Pediat, Chicago, IL 60612 USA
[2] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA
[3] Rush Univ, Med Ctr, Dept Biochem, Chicago, IL 60612 USA
[4] Rush Univ, Med Ctr, Dept Commun Disorders & Sci, Chicago, IL 60612 USA
[5] Washington Univ, Sch Med, Diabet Cardiovasc Dis Ctr, St Louis, MO USA
[6] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Dev Endocrinol & Genet, NIH, Bethesda, MD USA
[7] Rush Univ, Med Ctr, Dept Cell & Mol Med, Chicago, IL 60612 USA
基金
美国国家卫生研究院;
关键词
Niemann-Pick type C; Lysosomal storage disorder; Neurodegenerative disease; Cholesterol; Cyclodextrin; MIGLUSTAT THERAPY; ONSET; RELIABILITY; PROGRESSION; CHILDREN; DEFICITS; PATIENT; IQ; C1;
D O I
10.1016/j.pediatrneurol.2017.12.014
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Intrathecal 2-hydoxypropyl-beta-cyclodextrin has been found to mobilize cholesterol, extend life. reduce cerebellar pathology, and delay onset of ataxia in the mouse and cat models of Niemann-Pick disease, type C1, a clinically variable progressive and ultimately fatal neurodegenerative storage disorder characterized by endolysosomal accumulation of unesterified cholesterol. Objective: In this study, the long-term effects of intrathecal 2-hydoxypropyl-beta-cyclodextrin treatment for 2.5 to three years in humans with Niemann-Pick disease, type C, were evaluated. Methods: Three patients with Niemann-Pick disease, type C, in different stages of progression and displaying varying disease manifestations were treated with intrathecal 2-hydoxypropyl-beta-cyclodextrin (VTS-270) delivered by lumbar puncture infusion through an intermediate-size patient population investigational new drug application for expanded access. Disease progression was monitored with the Niemann-Pick disease, type C, Neurological Severity Scale and numerous objective measures of function in five neurological domains typically impacted by the disease: cognitive/language, gait/balance, fine motor, swallowing, and eye movement. Results: No worsening in any domain except eye movements (vertical pursuit gain) was seen for any of the three patients, and in the other domains, improved scores on measures were seen over time for one or more patients. The Niemann-Pick disease type C (NPC) Neurological Severity Scale (NSS) showed stable to slightly improved ratings. Conclusions: These trajectories are not consistent with the typical trajectory of the disease and suggest that intrathecal 2-hydoxypropyl-beta-cyclodextrin has stabilized the disease over an extended period of time, supporting the current phase 2/3 controlled registration trial with VTS-270. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:24 / 34
页数:11
相关论文
共 49 条
  • [1] Adams W., 2003, WRAML2: Wide range assessment of memory and learning: Administration and technical manual, V2nd
  • [2] [Anonymous], 2014, WECHSLER INTELLIGENC
  • [3] [Anonymous], 2006, Wechsler Intelligence Scale for Children-Third Edition
  • [4] Practice effects in healthy adults: A longitudinal study on frequent repetitive cognitive testing
    Bartels, Claudia
    Wegrzyn, Martin
    Wiedl, Anne
    Ackermann, Verena
    Ehrenreich, Hannelore
    [J]. BMC NEUROSCIENCE, 2010, 11
  • [5] Practice effects on the WAIS-III across 3-and 6-month intervals
    Basso, MR
    Carona, FD
    Lowery, N
    Axelrod, BN
    [J]. CLINICAL NEUROPSYCHOLOGIST, 2002, 16 (01): : 57 - 63
  • [6] Björkhem I, 1998, J LIPID RES, V39, P1594
  • [7] Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease
    Camargo, F
    Erickson, RP
    Garver, WS
    Hossain, GS
    Carbone, PN
    Heidenreich, RA
    Blanchard, J
    [J]. LIFE SCIENCES, 2001, 70 (02) : 131 - 142
  • [8] Hearing Loss and Hair Cell Death in Mice Given the Cholesterol-Chelating Agent Hydroxypropyl-β-Cyclodextrin
    Crumling, Mark A.
    Liu, Liqian
    Thomas, Paul V.
    Benson, Jennifer
    Kanicki, Ariane
    Kabara, Lisa
    Haelsey, Karin
    Dolan, David
    Duncan, R. Keith
    [J]. PLOS ONE, 2012, 7 (12):
  • [9] Chronic Cyclodextrin Treatment of Murine Niemann-Pick C Disease Ameliorates Neuronal Cholesterol and Glycosphingolipid Storage and Disease Progression
    Davidson, Cristin D.
    Ali, Nafeeza F.
    Micsenyi, Matthew C.
    Stephney, Gloria
    Renault, Sophie
    Dobrenis, Kostantin
    Ory, Daniel S.
    Vanier, Marie T.
    Walkley, Steven U.
    [J]. PLOS ONE, 2009, 4 (09):
  • [10] Delis D.C., 2001, DELIS KAPLAN EXECUTI